Investigating the pharmacokinetics of petrelintide using different drug product concentrations in participants with a BMI ≥27.0 kg/m2
ZP8396-25041
Phase 1 other active
Quick answer
Investigating the pharmacokinetics of petrelintide using different drug product concentrations in participants with a BMI ≥27.0 kg/m2 for Weight reduction is a Phase 1 program (other) at Zealand Pharma A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Zealand Pharma A/S
- Indication
- Weight reduction
- Phase
- Phase 1
- Modality
- other
- Status
- active